AstraZeneca, Chi-Med take kidney cancer drug into final testing

LONDON (Reuters) - AstraZeneca and Hutchison China MediTech said on Thursday they had initiated a global late-stage clinical trial of the experimental drug savolitinib in a relatively rare type of kidney cancer.